Biosimilar Antibodies

Fanastomig is a monoclonal antibody designed to target and inhibit both PDCD1 (Programmed cell death protein 1) and LAG3 (Lymphocyte activation gene-3). This dual-targeting approach enhances its potential for modulating immune responses, making it particularly relevant for research in immune checkpoint regulation and cancer immunotherapy.

Eclutatug is a humanized IgG1κ monoclonal antibody specifically targeting CLDN1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Safimestomig is a bispecific IgG4κ antibody designed to target CD47 and CD274. For experimental control purposes, the recommended isotype control is Human IgG4 (S228P) kappa. This control is essential for validating the specificity and ensuring the accuracy of bioassays involving Safimestomig.

Camrelizumab (SHR-1210) is a high-affinity, humanized IgG4-κ monoclonal antibody that targets the PD-1 receptor. This antibody demonstrates a binding affinity of 3 nM for PD-1 and effectively inhibits the PD-1/PD-L1 interaction with an IC50 of 0.70 nM. As an anti-PD-1/PD-L1 therapeutic agent, Camrelizumab is utilized in the investigation of various cancers, including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), Hodgkin lymphoma, and advanced hepatocellular carcinoma (HCC), among others. This specificity and potency make it a valuable tool in oncology research, facilitating the exploration of immune checkpoint pathways and their role in immune evasion by tumors.

Daclizumab (Zenapax) is a humanized monoclonal antibody designed to specifically target and block CD25, the α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA). By reversibly binding to CD25, Daclizumab inhibits the interaction between interleukin-2 (IL-2) and its receptor, thereby modulating the immune response. This antibody is primarily utilized in research focused on multiple sclerosis, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions in this disease.

Narsoplimab (OMS 721) is a fully human monoclonal antibody of the immunoglobulin gamma 4 (IgG4) subclass, characterized by its high affinity for MASP-2, effectively inhibiting the activation of the lectin pathway. This antibody is pivotal in research focused on hematopoietic stem-cell transplantation and the study of SARS-CoV-2, offering significant insights into therapeutic interventions and immune response mechanisms.

Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that targets programmed cell death protein 1 (PD-1). This antibody is designed for advanced research applications focusing on the modulation of immune checkpoints in oncological studies. Pucotenlimab facilitates the study of PD-1's role in tumor immune evasion and therapy response, providing a crucial tool for cancer research and potential therapeutic strategy development.

Libivirumab (17.1.41) is a human monoclonal antibody targeting the hepatitis B virus (HBV). It exhibits potent neutralizing activity against HBV surface antigen (HBsAg) and HBV e antigen (HBeAg), with half-maximal inhibitory concentrations (IC50) of 35 ng/mL and 130 ng/mL, respectively. This antibody is designed for use in research studies aimed at understanding HBV pathogenesis and for the development of therapeutic strategies against HBV infections.

Belimumab, also known as LymphoStat-B, is a humanized IgG1λ monoclonal antibody designed to target and neutralize B-lymphocyte stimulator (BLyS) protein. By antagonizing the activity of BLyS, Belimumab is utilized in the study of autoimmune disorders and B-cell malignancies. This antibody is particularly relevant for research focused on systemic lupus erythematosus (SLE), providing a valuable tool for understanding and potentially modulating disease mechanisms.

Telikibart is a human monoclonal antibody of the IgG1κ isotype, specifically designed to target the IL4 receptor (IL4R). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control. This antibody is pivotal in studies investigating the role of the IL4R in immune response and inflammatory processes.

Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody specifically targeting PSMA (Prostate-Specific Membrane Antigen). This antibody serves as the antigen-binding component of the antibody-drug conjugate (ADC) molecule, ARX517. For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

The Anti-HIV gp120 Antibody (55-36) is a chimeric mouse monoclonal antibody of the IgG1κ subtype designed specifically to target the HIV gp120 glycoprotein. This antibody serves as a crucial tool in the study of HIV infection mechanisms and the development of therapeutic strategies. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control with this antibody.

Bimekizumab is a humanized monoclonal antibody designed to selectively neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). These cytokines are known to promote osteogenic differentiation in human periosteum-derived cells (hPDCs). By targeting IL-17A and IL-17F, Bimekizumab effectively inhibits the inflammation-driven osteogenic differentiation, making it a valuable tool in research focused on inflammatory processes and bone metabolism.

The Anti-Complement Factor P/Properdin Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Complement Factor P, also known as Properdin, a critical component in the complement system that enhances the activation of the alternative pathway. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and exhibits a molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This product is ideal for use in research applications focused on the study of immune response modulation and complement system mechanisms.

Frexalimab (SAR441344) is a second-generation monoclonal antibody designed to target the CD40 ligand (CD40L). This antibody demonstrates a favorable safety profile and functions by inhibiting the interaction between CD40 and CD40L, thereby modulating the immune response. Frexalimab shows potential in preventing β-cell destruction, suggesting its utility in therapeutic research related to autoimmune diseases such as multiple sclerosis, lupus erythematosus, Sjögren’s syndrome, and type I diabetes.

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody engineered to target CLEC12A on myeloid cells and CD3 on cytotoxic T cells. CLEC12A is recognized as a myeloid differentiation antigen. This antibody facilitates the targeted destruction of both acute myeloid leukemia (AML) progenitor and stem cells. It achieves this through the induction of T cell-mediated cytotoxicity, leading to the proliferative lysis of AML cells. Tepoditamab (MCLA-117) is particularly valuable for research focused on the mechanisms and therapeutic interventions of acute myeloid leukemia.

Sabestomig is a monoclonal antibody targeting PDCD1 (Programmed Cell Death Protein 1) and HAVCR2 (Hepatitis A Virus Cellular Receptor 2), with an isotype composition of IgG1-κ and IgG1-λ2. This antibody is engineered for high specificity and affinity in binding to its targets, making it suitable for use in research studies focused on immune checkpoint pathways and their roles in immunology and oncology.

Zigakibart (BION-1301) is a humanized IgG4-kappa monoclonal antibody targeting TNFSF13, also known as tumor necrosis factor superfamily member 13, APRIL, or CD256. This antibody exhibits anti-inflammatory properties, making it a valuable tool for research into inflammatory processes and potential therapeutic interventions.

Anti-IL-13 Antibody (CNTO 607) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-13 (IL-13). This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, with an approximate molecular weight of 145 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. Anti-IL-13 Antibody (CNTO 607) is essential for research focused on the role of IL-13 in various biological processes and disease states, including allergic responses and other inflammatory conditions.

FZ-A038 is a humanized monoclonal antibody that specifically targets delta-like ligand 3 (DLL3). This antibody serves as a foundational component for the synthesis of the DLL3-targeted antibody-drug conjugate (ADC), FZ-AD005, offering potential applications in therapeutic development.

Rezorstobart is a human IgG1 κ monoclonal antibody targeting KLRB1. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. It specifically binds to the stem fusion domain in HA2, effectively neutralizing H1, H2, H5, and H9 subtypes of influenza A viruses. This antibody is crucial for studies focused on viral entry mechanisms and the development of broad-spectrum antiviral therapies.

Retavibart is a recombinant human respiratory syncytial virus (RSV) fusion glycoprotein F, designed for use in antiviral research. This product serves as a critical tool in the study of viral entry and fusion mechanisms of RSV. The isotype of Retavibart is Human IgG1 kappa, making it suitable for a variety of experimental setups requiring this specific control.

Secukinumab (AIN457) is a human monoclonal antibody with high affinity for interleukin-17A (IL-17A), representing the first-in-class anti-IL-17 agent. It is utilized in research focused on inflammatory diseases including plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. This specificity to IL-17A makes it a critical tool in the study of immune response mechanisms and therapeutic intervention in these conditions.

Ogalvibart (C-135-LS) is a human monoclonal antibody of the IgG1 subtype, specifically designed to target the SARS-CoV-2 virus. It exhibits high affinity binding to the receptor-binding domain (RBD) of the spike (S) glycoprotein on the virus surface. When used in conjunction with C144LS at a 1:1 ratio, Ogalvibart demonstrates significant preventive efficacy, effectively inhibiting the progression of COVID-19 in a rhesus monkey model. This antibody is pivotal for research focused on the mechanisms of SARS-CoV-2 infection and the development of therapeutic strategies.

Anti-IL-13 (M1295) is a humanized monoclonal antibody specifically targeting interleukin-13 (IL-13). This antibody binds with high affinity to IL-13, a key cytokine involved in inflammatory responses, making it an essential tool for research in immunology and inflammation. Anti-IL-13 (M1295) is suitable for a variety of applications, including flow cytometry, western blotting, and immunohistochemistry, providing valuable insights into the role of IL-13 in disease processes such as asthma and allergies.

Garetatug is a humanized monoclonal antibody designed to target and bind specifically to human Claudin-18 (CLDN18), a tight junction protein. By binding to CLDN18, Garetatug disrupts critical cell signaling pathways, thereby exerting antitumor effects. This antibody is utilized primarily in research focused on the mechanisms of tumor progression and therapeutic intervention.

The Anti-Haptoglobin Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Haptoglobin, a key protein involved in hemoglobin binding and iron recovery. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for use in a variety of immunodetection methodologies to study or quantify Haptoglobin levels in biological samples.

Masavibart (ZRC3308-A7) is a monoclonal antibody of the IgG1 subtype, specifically designed to target SARS-CoV-2. This antibody exhibits strong binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Masavibart can be co-administered with ZRC3308-B10 in a 1:1 ratio. This combination has shown potential in the prevention of COVID-19, particularly effective in the initial stages of the disease, prior to the onset of severe symptoms.

Inolimomab is a monoclonal antibody targeting the α chain of the interleukin-2 receptor (IL-2R). This antibody has shown potential in early-stage research for enhancing survival rates in patients with acute graft-versus-host disease (aGVHD). Its mechanism involves the specific inhibition of IL-2R, a critical regulator in the activation and proliferation of T lymphocytes, which play a significant role in the pathogenesis of aGVHD.

Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody engineered to target the extracellular domains of HER2 and HER3 with its two distinct Fab arms. This dual specificity facilitates the inhibition of downstream signaling pathways that are critical for tumor growth and survival, making it a valuable tool for research in cancer biology, particularly in studies focused on breast and gastric cancers.

Gosuranemab (BMS-986168) is a humanized IgG4 monoclonal antibody specifically designed to target and bind to the N-terminal residues 15-22 of the tau protein in humans. This antibody is primarily explored for its potential applications in Alzheimer’s disease research, focusing on its ability to interact with tau, a protein implicated in the pathogenesis of neurodegenerative disorders.

The Anti-CD36 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CD36, a transmembrane glycoprotein involved in fatty acid metabolism, phagocytosis, and angiogenesis. This antibody consists of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is essential for research focusing on cardiovascular diseases, metabolic disorders, and immune response modulation.

Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 monoclonal antibody specifically designed to target the receptor-binding domain of the SARS-CoV-2 spike (S) glycoprotein. This antibody binds with high specificity and affinity, making it a valuable tool for research focused on viral entry mechanisms, neutralization assays, and therapeutic intervention studies related to COVID-19.

CHS-114 (SRF-114) is a fully human IgG1 monoclonal antibody designed to specifically target CCR8. This antibody has demonstrated potential utility in research focused on head and neck squamous cell carcinoma (HNSCC). For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control.

Volociximab (M200), a chimeric human/murine IgG4 monoclonal antibody, selectively targets integrin α5β1 with an EC50 of 0.2 nM. Integrin α5β1, a principal receptor for fibronectin, plays a crucial role in angiogenesis. Volociximab exhibits potent antiangiogenic and antitumor properties, effectively inhibiting the proliferation of human umbilical vein vascular endothelial cells (HUVECs). This antibody is instrumental in research focused on the mechanisms of angiogenesis and potential therapeutic strategies for cancer treatment.

Foralumab (NI-0401) is a potent, orally active human monoclonal antibody that specifically targets CD3. This antibody plays a crucial role in modulating immune responses. It has demonstrated efficacy in NSG mice reconstituted with human hematopoietic stem cells, making it an invaluable tool for research into immune regulation and potential therapeutic applications.

Elotuzumab is a monoclonal antibody that specifically targets the SLAMF7 receptor. While it demonstrates minimal antimyeloma activity as a monotherapy in cases of relapsed or refractory multiple myeloma (RRMM), its efficacy is significantly enhanced when used in conjunction with other antimyeloma agents. This combination therapy has been shown to improve both response rates and overall outcomes in multiple myeloma treatment.

Ralzapastotug (AB-308) is a monoclonal antibody of the IgG1 subclass designed to specifically target the TIGIT receptor (T cell immunoreceptor with Ig and ITIM domains). This antibody binds to the amino acid sequence 106-126 of the cellular prion protein PrP^C, indicating a precise specificity that may be critical in modulating immune responses. Ralzapastotug is particularly relevant in research focused on immune checkpoint pathways and could be instrumental in studies exploring therapeutic interventions in oncology and immunological disorders.

Sonavibart is a human monoclonal antibody of the IgG1κ subtype that specifically targets the hemagglutinin HA protein of influenza A virus. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

The Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a chimeric mouse monoclonal antibody of the IgG1 subclass, specifically designed to target the human CD220, also known as the Insulin Receptor. This antibody recognizes and binds to the insulin receptor, facilitating studies on receptor expression and function in various biological contexts. For accurate isotype control in experimental setups, it is recommended to use Mouse IgG1 kappa Isotype Control to ensure specificity and consistency in results.

Donzakimig is a monoclonal antibody designed to target and inhibit the activity of interleukin 13 (IL-13), interleukin 22 (IL-22), and albumin (ALB). This antibody is engineered for high specificity and affinity, making it an ideal tool for research into the biological roles and interaction mechanisms of these cytokines and proteins. Donzakimig is suitable for use in various immunological assays to explore the pathophysiological implications of IL-13, IL-22, and ALB in disease states, providing valuable insights for therapeutic development.

Osocimab (BAY 1213790) is a potent anti-FXIa monoclonal antibody, characterized by a dissociation constant (Ki) of 2.4 nM and a half-maximal effective concentration (EC50) of 0.2 nM. This antibody targets Factor XIa (FXIa), a key enzyme in the coagulation cascade, and its inhibition is associated with a reduced risk of thrombosis. Osocimab effectively inhibits thrombin generation and prolongs the activated partial thromboplastin time (aPTT), demonstrating significant anticoagulant properties. This makes it a valuable tool for studies focused on the regulation of blood coagulation and the development of therapeutic strategies for thrombotic disorders.

Imneskibart is a humanized IgG1κ monoclonal antibody specifically targeting IL-2RA. For experimental control, the recommended isotype control is Human IgG1 kappa Isotype Control.

Toripalimab is a selective, recombinant, humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. This antibody binds specifically to PD-1, effectively blocking its interaction with PD-L1 and PD-L2 ligands. Through this mechanism, Toripalimab disrupts the PD-1 mediated signaling pathway, which is critical in regulating the immune system's response to cancer cells. Clinically, Toripalimab has demonstrated significant anti-tumor activity across a range of malignancies, including melanoma, lung cancer, various digestive tract tumors, hepatobiliary and pancreatic cancers, neuroendocrine tumors, nasopharyngeal carcinoma, and urothelial carcinoma. This antibody is pivotal in research focused on immunotherapy and the immune evasion strategies of tumors.

Trastuzumab is a humanized IgG1 monoclonal antibody specifically designed for targeting and neutralizing HER2, a protein overexpressed in certain invasive breast cancers. This antibody is crucial for research focused on HER2-positive metastatic breast cancer and HER2-positive gastric cancer, providing a valuable tool for understanding disease mechanisms and developing therapeutic strategies.